Reactions of Auranofin and Its Pseudohalide Derivatives with Serum Albumin Investigated through ESI-Q-TOF MS.

The reactions of auranofin and three pseudohalide derivatives with bovine serum albumin were explored by ESI-Q-TOF mass spectrometry; a detailed molecular description of the resulting adducts is achieved revealing even subtle differences in reactivity within this series of gold(I) complexes. Our study shows that this kind of investigative approach, formerly applied to the interactions of metal-based drugs with small model proteins of MW 10-15 kDa, e.g., cytochrome c and lysozyme, may now be extended with success to far larger proteins such as serum albumin (MW 66 kDa).

[1]  B. Arulanandam,et al.  Repurposing Auranofin, Ebselen, and PX-12 as Antimicrobial Agents Targeting the Thioredoxin System , 2018, Front. Microbiol..

[2]  Wen-Qi Jiang,et al.  Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis , 2018, Cell Death & Disease.

[3]  A. Lapucci,et al.  Selection and characterization of a human ovarian cancer cell line resistant to auranofin , 2017, Oncotarget.

[4]  A. Arcangeli,et al.  Auranofin, Et3PAuCl, and Et3PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study. , 2017, ACS medicinal chemistry letters.

[5]  M. Naldi,et al.  Simple and rapid LC–MS method for the determination of circulating albumin microheterogeneity in veal calves exposed to heat stress , 2017, Journal of pharmaceutical and biomedical analysis.

[6]  L. Messori,et al.  ESI–MS studies of the reactions of novel platinum(II) complexes containing O,O′-chelated acetylacetonate and sulfur ligands with selected model proteins , 2017, BioMetals.

[7]  L. Messori,et al.  Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments. , 2017, Talanta.

[8]  C. Day,et al.  Human Serum Albumin-Delivered [Au(PEt3)]+ Is a Potent Inhibitor of T Cell Proliferation. , 2017, ACS medicinal chemistry letters.

[9]  G. Turcatti,et al.  Repositioning approved drugs for the treatment of problematic cancers using a screening approach , 2017, PloS one.

[10]  T. Hazbun,et al.  Repurposing Approach Identifies Auranofin with Broad Spectrum Antifungal Activity That Targets Mia40-Erv1 Pathway , 2017, Front. Cell. Infect. Microbiol..

[11]  L. Messori,et al.  New gold carbene complexes as candidate anticancer agents , 2016, BioMetals.

[12]  A. Colombatti,et al.  Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma. , 2015, Blood.

[13]  L. Massai,et al.  Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The comparison with auranofin. , 2015, Journal of inorganic biochemistry.

[14]  J. Delcour,et al.  Formation and reshuffling of disulfide bonds in bovine serum albumin demonstrated using tandem mass spectrometry with collision-induced and electron-transfer dissociation , 2015, Scientific Reports.

[15]  J. Reisz,et al.  Mass spectrometry in studies of protein thiol chemistry and signaling: opportunities and caveats. , 2015, Free radical biology & medicine.

[16]  B. Keppler,et al.  Efficiently Detecting Metallodrug–Protein Adducts: Ion Trap versus Time‐of‐Flight Mass Analyzers , 2014, ChemMedChem.

[17]  A. Casini,et al.  Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs. , 2013, Chemical Society reviews.

[18]  L. Massai,et al.  Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme , 2012, JBIC Journal of Biological Inorganic Chemistry.

[19]  M. Gómez-Gómez,et al.  Top-down mass spectrometric approach for the full characterization of insulin-cisplatin adducts. , 2009, Analytical chemistry.

[20]  A. Casini,et al.  Exploring metallodrug–protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound , 2009, JBIC Journal of Biological Inorganic Chemistry.

[21]  A. Casini,et al.  Peculiar mechanistic and structural features of the carboplatin–cytochrome c system revealed by ESI-MS analysis , 2008, JBIC Journal of Biological Inorganic Chemistry.

[22]  S. Ralph,et al.  A mass spectrometric investigation of the binding of gold antiarthritic agents and the metabolite [Au(CN)2]− to human serum albumin , 2006, JBIC Journal of Biological Inorganic Chemistry.

[23]  B. Freeman,et al.  Sulfenic acid in human serum albumin , 2006, Amino Acids.

[24]  D. Gibson,et al.  Mass spectrometric studies of the formation and reactivity of trans-[PtCl2(Am)(piperidinopiperidine)] x HCl complexes with ubiquitin. , 2005, Rapid communications in mass spectrometry : RCM.

[25]  P. Lee,et al.  Homocysteine and cysteine – albumin binding in homocystinuria: assessment of cysteine status and implications for glutathione synthesis? , 2002, Amino Acids.

[26]  C. Shaw,et al.  Ligand-scrambling reactions of cyano(trialkyl/triarylphosphine)gold(I) complexes: examination of factors influencing the equilibrium constant , 1990 .

[27]  W. Scovell,et al.  Synthesis and spectroscopic characterization of (triethylphosphine)gold(I) complexes AuX(PEt3) (X = Cl, Br, CN, SCN), [AuL(PEt3)+] (L = SMe2, SC(NH2)2, H2O), and (.mu.-S)[Au(PEt3)]2 , 1990 .

[28]  A. Isab,et al.  Reactions of trimethylphosphine analogues of Auranofin with bovine serum albumin , 1988 .

[29]  Guy Godin,et al.  Gold , 1895, The Hospital.